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Abstract
Despite the initial promise of metal-on-metal (MoM) implants as the ideal bearing surface for hip 
replacements and resurfacings, high short term failure rates due to an adverse reaction to metal 
debris (ARMD) have led to a dramatic reduction in the number of MoM implants used in the 
modern era. With over one million patients worldwide having undergone hip operations utilizing a 
MoM bearing surface, the long term outcomes for such patients remains unknown, and there is much 
debate as to the most effective management of these patients. Although several regulatory bodies 
have released guidelines on the management of patients with MoM hips, these recommendations 
remain open to interpretation, and the most effective management for these patients remains unclear. 
The aim of this review is to compare the current guidelines for managing patients with MoM hips 
and also to discuss established ARMD risk factors, evidence regarding the optimum management for 
patients with MoM hips, and the indications for revision surgery. Furthermore, although specialized 
laboratory tests and imaging can be used to facilitate clinical decision making, over-reliance on any 
single tool should be avoided in the decision making process, and surgeons should carefully consider 
all findings when determining the most appropriate course of action.
Keywords: Adverse reaction to metal debris, follow up, guideline, hip replacement, hip resurfacing, 
metal-on-metal, patient management
MeSH terms: Replacement, arthroplasty, hip, reoperation, prosthesis
Management Guidelines for Metal-on-metal Hip Resurfacing Arthroplasty: 
A Strategy on Followup
Naoki Nakano, 
Andrea Volpin, 
Jonathan Bartlett, 
Vikas Khanduja
Department of Trauma and 
Orthopaedics, Addenbrooke’s 
Hospital, Cambridge University 
Hospitals NHS Foundation 
Trust, Cambridge, CB2 0QQ, 
UK
Introduction
The increasing incidence of 
polyethylene associated complications in 
Metal-on-Polyethylene (MOP) bearings in 
the early 2000s led to a resurgence of the 
metal-on-metal (MoM) bearing in total hip 
arthroplasty (THA) surgery.1 Initial promise 
from MoM THAs was rooted in a proposed 
reduction in failure rates due to diminished 
volumetric wear, greater component stability, 
and avoidance of polyethylene wear-induced 
osteolysis.2,3 Parallel to this, MoM bearing 
was found to have a number of unique 
advantages in hip resurfacing. These 
included the ability to preserve bone stock 
in the younger patients, low dislocation 
rates, improved proprioception and gait, and 
the perceived ease of future conversion to a 
THA.4 In addition, it has been suggested that 
it is safe to return to high impact activity 
following hip resurfacing – something highly 
valuable to younger individuals undergoing 
hip resurfacing procedures.5
Despite these initial benefits, high short 
term failure rates due to adverse reaction 
to metal debris (ARMD) in MoM bearings 
have been reported, leading to concerns 
over their use.6-11 ARMD is the sequelae 
of metal debris released from MoM 
bearings due to wear and corrosion.12 This 
process results in destructive soft-tissue 
masses adjacent to the bearing and 
often necessitates surgical revision. As 
such, ARMD lesions have been branded 
“inflammatory pseudotumor.”13 Although 
the size of particulate matter generated 
by a MoM bearing is significantly smaller 
than that of a MoP bearing, these adverse 
inflammatory effects are theorized to be 
the result of a greater volume of particle 
generation and these particles being much 
more biologically active.14 In addition, the 
significant bone loss and muscle damage 
that results from ARMD means that 
short-term outcomes following revision 
surgery are often poor.15,16 These poor 
outcomes have attracted particular attention 
as most patients who received MoM 
bearings are young and active.17-19
The poor outcomes associated with 
MoM bearings, and the subsequent 
recall of specific implants has led to a 
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dramatic reduction in the number of MoM THA and 
hip resurfacing procedures performed today. However, 
as over a million patients worldwide have already been 
implanted with MoM devices, a clear management 
strategy for patients with MoM hips is essential.20 
Regulatory authorities have published guidance on the 
regular followup and management of patients with MoM 
hips.21-26
Metal-on-metal management guidelines
Management guidelines for MoM hips have been published 
by five authorities in various countries and regions. These 
include:
1. United States of America Food and Drug 
Administration (FDA)21
2. United Kingdom Medical and Healthcare Products 
Regulatory Agency (MHRA)22
3. European Federation of National Associations of 
Orthopaedics and Traumatology (EFORT)23
4. Health Canada26
5. Therapeutic Goods Administration of Australia (TGA).25
Surveillance strategy guidance
Each authority provides guidance on the patient selection 
for followup, and the frequency at which this should occur 
[Table 1].
Symptomatic and asymptomatic metal-on-metal hip 
investigations and imaging
Each of the five authorities also provide guidance regarding 
the investigations and imaging patients with MoM hips 
should receive [Table 2], and further discusses which 
metal ions should be sampled and the acceptable values for 
each [Table 3].
Which patients are at risk of adverse reaction to metal 
debris?
Patients can be stratified into high- and low-risk groups 
depending on implant specific and patient specific factors. 
Implant specific factors that increase the risk of ARMD are 
THAs with large diameter femoral head components or the 
DePuy ASR implants. In addition, several implant specific 
factors correlate with a lower risk of ARMD, including 
THAs with small diameter femoral head components, and 
hip resurfacing implants.22 Several studies have described 
patient factors associated with increased failure rates in 
MoM hips. In a systematic review, an increased risk of 
developing ARMD, and higher rates of dislocation, aseptic 
loosening and revision after MoM hip resurfacings were 
found in female patients.27 Although the reasons for this 
finding are unclear, it has been theorized that the higher 
prevalence of developmental dysplasia in females may 
affect the accuracy of acetabular component positioning, 
resulting in higher rates of impingement, edge loading, 
and wear.28 In addition, metal hypersensitivity has been 
reported as an important factor in the pathology of ARMD 
following histological examination of peri prosthetic 
tissue.29,30 Another theorized risk factor for ARMD is that of 
low body mass index (BMI). A recent study demonstrated 
a negative correlation between BMI and elevated Cr 
level.28 Although the authors suggested that differences in 
activity level could explain this relationship, further studies 
Table 1: Surveillance strategy guidance by authorities
Authority Recommended followup schedule 
for asymptomatic patients
Recommended followup schedule 
for symptomatic patients
Additional guidance
FDA* Every 1-2 years Every 6 months Closer followup should be considered for those 
with increased risk factors of increased device 
wear. These include female, those who received hip 
resurfacing with a small femoral head component 
(≤44 mm), those with bilateral hip implants, and 
those with suboptimal component alignment
MHRA Annual followup for THA cases with 
large femoral head component (≥36 
mm)
Annual followup for hip 
resurfacing cases
No guidelines are given for patients that do not 
meet these criteria
EFORT Annual followup for THA cases with 
a large femoral head component (≥36 
mm) and hip resurfacing cases with 
defined risk factors for ARMD
No specific guidelines provided Defined risk factors are described as female gender, 
low coverage arc, and small femoral head size
Health 
Canada*
Annual followup for first 5 years for 
asymptomatic patients with MoM hips
No specific guidelines provided N/A
TGA Annual follow-up for cases with 
large (≥45) or small (≤36) femoral 
head components
TGA Australia recommends annual 
followup for symptomatic patients 
with MoM hip cases
No guidelines given for patients other than those 
described
*Unlike other authorities, the FDA and Health Canada make no distinction between the followup of hip replacement and hip resurfacing. 
FDA=Food and Drug Administration, MHRA=Medical and Healthcare Products Regulatory Agency, EFFORT=European Federation 
of National Associations of Orthopedics and Traumatology, TGA=Therapeutic Goods Administration, THA=Total hip arthroplasty, 
ARMD=Adverse reaction to metal debris, MoM=Metal-on-metal, N/A=Not available
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assessing activity level in isolation have shown this not to 
be the case.31
What is the evidence base for the frequency of followup?
As asymptomatic ARMD lesions have been observed in 
up to 61% of MoM hips, followup strategies according 
to symptoms will result in undetected ARMD in a 
large number of patients.32-34 This necessitates regular 
investigations to identify asymptomatic ARMD.
The necessity of blood metal ion concentration testing has 
been repeatedly demonstrated, with higher complication 
rates shown in patients with elevated blood metal ion 
concentrations.7,35-37 However, the optimum frequency 
of these blood test remains unclear. One study found 
that blood metal ion levels in patients with MoM THAs 
increased significantly over an 8-month period and that 
similar increases were not shown in patients who received 
hip resurfacing.38 This led the researchers to suggest that 
annual blood metal ion measurements are of values in 
THA followup but not in hip resurfacing. An additional 
study found that repeating blood metal ion measurements 
at a mean postoperative time of 27 months in MoM hip 
resurfacing cases showed no significant increases in 
Co when compared to the concentration after surgery.36 
Although these findings highlight the ambiguity with 
regards to optimum followup frequency, elevated blood 
levels require further investigation. One study has suggested 
that if metal ion levels are elevated, radiographs should 
be evaluated for osteolysis and inappropriate component 
position. If either is found, then revision surgery should be 
considered.39
In addition to the unclear evidence regarding metal ion 
blood tests, the benefits of short-term imaging are also 
questionable. Two previous studies have suggested that 
patients with normal initial imaging do not need repeat 
imaging in the short-term, as no significant change was 
found when repeat imaging was performed at various 
time intervals.40,41 However, the usefulness of magnetic 
resonance imaging (MRI) scans in surgical decision 
making decreases drastically if not regularly updated. 
One study demonstrated that MRI scans performed 
over 12 months previously had a sensitivity of 29%. This 
was compared to a sensitivity of 88% for scans that were 
3-month-old.42 From these results, it was suggested that 
repeat imaging should be performed at least annually, 
and the usefulness of results over a year old severely 
questioned. Furthermore, as cyst progression has not been 
observed earlier than 6 months postoperatively, annual 
followup has been recommended in other studies.43 In 
addition, although some work has begun to assess the 
time-course of growth of the pseudotumors, there is a large 
discrepancy between results. Growth of pseudotumors, 
remission of small masses, and static pseudotumors have 
all been documented, highlighting the need for a greater 
Table 2: Guidance regarding investigation and imaging of MoM hips by authorities
Authority Guidance regarding investigation and imaging of 
asymptomatic MoM hips
Guidance regarding investigation and 
imaging of symptomatic MoM hips
FDA No guidance provided Radiograph of hips, imaging (MARS MRI, 
CT or ultrasound) and metal ion sampling
MHRA Metal ion sampling for asymptomatic THA cases, and imaging 
is recommended if blood metal ion levels rise
Metal ion sampling and imaging (MARS 
MRI or ultrasound)
EFORT Radiographs and metal ion sampling for all asymptomatic hips. 
Further imaging for asymptomatic hips with an abnormality in 
radiographs, or with Co concentrations between 2-7 µg/L
Radiograph of hips, imaging (MARS MRI, 
CT or ultrasound) and metal ion sampling
Health 
Canada
No guidance provided Radiographs, imaging (MARS MRI or 
ultrasound) and metal ion sampling
TGA Radiographs, imaging and metal ion sampling for cases with 
femoral heads ≤36 mm or ≥45 mm
Radiographs, imaging (MARS MRI or 
ultrasound) and metal ion sampling
FDA=Food and Drug Administration, MHRA=Medical and Healthcare Products Regulatory Agency, EFFORT=European Federation 
of National Associations of Orthopedics and Traumatology, TGA=Therapeutic Goods Administration, MARS=Metal artifact reduction 
sequence, MRI=Magnetic resonance imaging, CT=Computed tomography, MoM=Metal-on-metal, THA=Total hip arthroplasty
Table 3: Metal ion sampling recommendations and advised thresholds by authorities
Authority Metal ion sampling recommendations Thresholds advised
FDA Sampling of whole blood cobalt and chromium Not provided
MHRA Sampling of whole blood cobalt and chromium Concentrations above 7 µg/L should be a cause for concern
EFORT Sampling of whole blood cobalt only Asymptomatic patients with concentrations between 2 µg/L 
and 7 µg/l require cross-sectional imaging
Health Canada Sampling of whole blood and serum cobalt and chromium Concentrations above 7 µg/L should be a cause for concern
TGA Sampling of whole blood or serum cobalt and chromium Not provided
FDA=Food and Drug Administration, MHRA=Medical and Healthcare Products Regulatory Agency, EFFORT=European Federation of 
National Associations of Orthopaedics and Traumatology, TGA=Therapeutic Goods Administration
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understanding of ARMD pathology if we are to establish 
effective monitoring protocols.41,44
Thresholds for concern with metal ion levels
Metal ion levels have been extensively used as a 
surrogate marker for patients with MoM bearings related 
wear.45 The population background level of Co in blood 
has been shown to be 0.5 µg/L, and the mean Co blood 
levels in patients with well functioning MoM hip implants 
ranges between 0.2 and 4 µg/L.46 There is correlation seen 
with wear rates of the MoM joint, where blood levels 
of 2 µg/L can be expected with wear rates of 2 mm3/
years.37,47 In addition, Co and Cr ion levels are influenced 
by the type of MoM implant, head size, implant design, 
and component positioning.48,49 Although one study has 
shown that Co is more reliable than Cr, and that whole 
blood testing is quicker and more accurate than serum, 
either whole blood or serum, and Co or Cr, can be 
used for monitoring as long as the testing modality is 
consistent.46,50 Furthermore, there should be standardized 
protocols in place for the collection of serum or blood 
samples, as needle type and collection techniques can 
influence reported ion concentrations.25,26
A retrospective study evaluating the use of Co and Cr blood 
sampling established that cut-off value of 7 µg/L had a 
specificity of 89% and a sensitivity of 52% in detecting 
failed MoM articulations in patients with normal imaging 
results, and has been extensively adopted.51 Similarly, Hart 
et al. demonstrated 93% specificity with a threshold set 
at 7 µg/L.37 Although no single metal ion threshold will 
reliably identify all ARMD patients, EFORT suggests that 
7 µg/L may be too high a threshold, instead recommending 
a threshold of between 2 µg/L and 7 µg/L, with the exact 
level still to be determined. In addition, the interpretation 
of metal ion levels can be difficult in patients with a 
systemic renal disease or additional metallic implants, such 
as in patients with bilateral MoM implants. Therefore, 
metal ions levels should be used to guide and should not 
be used in isolation to determine the need for revision 
surgery.36,52 Surgeons must carefully consider findings from 
clinical examination, blood test results, and radiologic 
investigations when determining the likelihood of a failing 
MoM THA or hip resurfacing.
The essence of clinical examination
Physical examination is essential in the assessment of 
painful hips in patients with MoM implants. Patients 
with ARMD commonly present with early recurrence of 
preoperative symptoms, or with persistent pain. In addition, 
radiation of pain to the greater trochanter and down 
the thigh is a common feature and can result in patients 
displaying an antalgic gait.53 Patients may also present 
with a palpable mass or fluid collection near the hip.54 
Over time, this may progress to instability, with or without 
dislocation, and patients may complain of a “clicking” 
or “clunking” sensation in the hip. Patients may also 
experience other symptoms, such as stiffness or reduced 
range of movement often most evident in the abduction. 
It is, therefore, imperative to assess the active and passive 
range of motion of the hip joint. Reproduction of pain 
on passive extension and active flexion may indicate 
concomitant iliopsoas tendinopathy. Abductor weakness 
may indicate peri-prosthetic soft-tissue involvement and is 
occasionally accompanied by a rash indicating a reaction to 
the metal ions.55
It is vital to obtain a complete history, perform a thorough 
clinical examination, and conduct relevant investigations 
to exclude other potential diagnoses. As joint sepsis must 
be suspected in patients with a history of complicated 
wound healing, physical examination of the skin should 
be performed, looking for signs of infection and previous 
scars. A comprehensive spine and neurovascular examination 
should also be performed to evaluate possible neurogenic 
and vascular pain generators.48 Due to the destructive nature 
of ARMD, appropriate assessment in a timely manner is 
essential. Due to the high rate of asymptomatic pseudotumors, 
it is also very important for general practitioners to remain 
vigilant when examining any patient who has previously 
undergone a MoM THA or a hip resurfacing.
When should revision surgery be considered and 
conducted?
All the authorities recommend revision surgery in patients 
with abnormal cross-sectional imaging and/or rising blood 
metal ions. In addition, the FDA recommends deciding 
on revision surgery in the context of the overall clinical 
picture, examination findings and test results, and further 
suggests early revision surgery in patients with progressive 
lesions. Both MHRA and EFORT recommend revision 
surgery if there are abnormal imaging findings and/or 
if increasing blood metal ion levels are found. EFORT 
further suggests that a blood Co level above 20 µg/L is 
an indication for revision. Conversely, Health Canada 
recommends revision surgery if patients are symptomatic 
and if a positive MRI appearance (soft tissue mass) is 
found. They also suggest revision surgery in asymptomatic 
cases if a soft-tissue mass, or masses, found on MRI are 
increasing in size. TGA recommends revision surgery if 
symptoms are persistent with imaging abnormalities and/or 
increasing of blood metal ions.
Poor short term outcomes have been reported following 
ARMD revision, with only a few studies assessing 
prognostic factors of post revision outcome.15,16,18,56,57 One 
study attributed improved outcomes following ARMD 
revision to early surgery and increased experience.57 In the 
latest internationally recognized guidelines published by 
Scientific Committee on Emerging and Newly Identified 
Health Risks (SCENIHR), there was no consensus on 
the appropriate timing of revision surgery for ARMD 
in MoM THA or hip resurfacings.24 SCENIHR do 
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however recommended that revision should be considered 
when symptoms become persistent, progressive, and 
unmanageable. Furthermore, they suggest that any patient 
exhibiting progressive osteolysis, expanding or large 
pseudotumors, progressive neck thinning or very high 
metal ion concentrations should also be considered for 
revision surgery.24 Although these recommendations are 
useful until prognostic factors of adverse outcomes are 
identified, the need for defined thresholds for revision 
surgery is paramount. Surgeons should keep in mind 
that a decision to revise should not be based on a single 
investigation. Instead, the decision should take the implant 
type, patient symptoms, imaging findings, metal ion levels, 
and the activity levels of the patient into account. When 
revising MoM implants, it is recommended to utilize a 
non-MoM articulation such as ceramic-on-ceramic or 
ceramic-on-polyethylene to reduce local metal ion release 
to decrease the chance of recurrence of ARMD, because 
poorer outcomes have been reported in patients revised 
using MoM articulations.58
Conclusion
Patients with MoM bearings should be monitored 
closely with physical examination, radiographs, metal 
ion measurement, and imaging. Evidence supporting the 
management of MoM hips is still lacking in many scenarios, 
and regulatory guidelines are open to interpretation. When 
considering revision surgery, no single investigation or 
aspect of the history should be taken in isolation. Decisions 
should be taken on a case-by-case basis, with consideration 
given to all aspects of investigation results and the patient’s 
clinical condition. Until supporting evidence is available, 
an evidence-based multidisciplinary approach is considered 
a safe method to help surgeons make decisions and 
potentially improve patient outcomes.
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